Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers

PHASE3TerminatedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

April 14, 2020

Primary Completion Date

May 13, 2020

Study Completion Date

March 30, 2022

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine Oral Tablets

DRUG

Placebo of Hydroxychloroquine

Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets

DRUG

Lopinavir and ritonavir

LPV/r Oral Tablets

DRUG

Placebo of LPV/r Tablets

Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets

Trial Locations (9)

33000

CHU de Bordeaux, Bordeaux

34000

CHU de Montpellier, Montpellier

35000

CHU de Rennes, Rennes

44000

CHU de Nantes, Nantes

54000

CHU de Nancy, Nancy

63000

CHU de Clermont-Ferrand, Clermont-Ferrand

76000

CHU de Rouen, Rouen

Unknown

CHU d'Angers, Angers

CHU de Saint-Etienne, Saint-Etienne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Institut Pasteur

INDUSTRY

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT04328285 - Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers | Biotech Hunter | Biotech Hunter